<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00136552</url>
  </required_header>
  <id_info>
    <org_study_id>FL2000</org_study_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT00136552</nct_id>
  </id_info>
  <brief_title>Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden</brief_title>
  <official_title>FL-2000 Study for Newly Diagnosed Follicular Lymphoma Patients With a High Tumor Burden</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lymphoma Study Association</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lymphoma Study Association</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess in a prospective multicentric study (Phase III) the
      introduction of a monoclonal antibody directed against B-cells associated with a standard
      therapy including chemotherapy and alpha-interferon in first line treatment of patients with
      a large tumor burden follicular lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Follicular lymphoma patients with a large tumor burden will be randomized for 18 months of
      treatment with either:

        -  Arm A: CHVP + alpha2a-interferon. Patients will receive 12 courses of CHVP
           (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and
           prednisolone 40 mg/m² for 5 days), one course every month for 6 months then one course
           every other month for 12 additional months associated with alpha2a-interferon 4.5
           millions units sub-cutaneously three times a week for 18 months.

        -  Arm B: CHVP + alpha2a-interferon + rituximab. Patients will receive 6 monthly courses of
           CHVP (cyclophosphamide 600 mg/m², adriamycin 25 mg/m², etoposide 100 mg/m² on day 1 and
           prednisolone 40 mg/m² for 5 days) associated with 6 infusions of rituximab (375 mg/m2)
           associated with alpha2a-interferon 4.5 millions units sub-cutaneously three times a week
           for 18 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2000</start_date>
  <completion_date>December 2004</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment>360</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed follicular lymphoma with a biopsy performed in the last 3
             months

          -  Patients previously untreated.

          -  Patients with at least one of the following symptoms requiring initiation of
             treatment:

               -  Bulky disease at study entry according to the Groupe d'Etudes Lymphomes
                  Folliculare (GELF) criteria: nodal or extranodal mass &gt; 7cm in its greater
                  diameter

               -  B symptoms

               -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) &gt; 1

               -  Elevated serum lactate dehydrogenase (LDH) or beta2-microglobulin

               -  Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm)

               -  Symptomatic splenic enlargement

               -  Compressive syndrome

               -  Pleural/peritoneal effusion

          -  Age must be &gt; 18 years and less than 76 years

          -  Having previously signed a written informed consent form.

        Exclusion Criteria:

          -  Transformation to high-grade lymphoma (secondary to “low-grade” follicular lymphoma).

          -  Patients without a large tumor burden.

          -  Patients with prior or concomitant malignancies except non-melanoma skin cancer or
             adequately treated in situ cervical cancer.

          -  Poor renal function: Serum creatinine &gt; 150 μmol/L,

          -  Known HIV infection or active hepatitis B virus (HBV) or hepatitis C virus (HCV)
             infection.

          -  Patients with contra-indication to interferon, adriamycin, or rituximab.

          -  Serious underlying medical conditions, which could impair the ability of the patient
             to participate in the trial (e.g. ongoing infection, uncontrolled diabetes mellitus,
             gastric ulcers, active autoimmune disease). Judgment is up to the investigator.

          -  Known sensitivity or allergy to murine products

          -  Adult patient under tutelage.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilles A Salles, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lymphoma Study Association</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Groupe d'Etude des Lymphomes de l'adulte</name>
      <address>
        <city>Mont-Godinne</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Hématologie - Centre Hospitalier Lyon-Sud</name>
      <address>
        <city>Pierre-Bénite cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.gela.org</url>
    <description>Official site of the Groupe d'Etudes des Lymphomes de l'Adulte (In french)</description>
  </link>
  <reference>
    <citation>Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, et al. Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte. N Engl J Med. 1993 Nov 25;329(22):1608-14.</citation>
    <PMID>8232429</PMID>
  </reference>
  <reference>
    <citation>McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998 Aug;16(8):2825-33.</citation>
    <PMID>9704735</PMID>
  </reference>
  <verification_date>July 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2005</study_first_posted>
  <last_update_submitted>July 2, 2007</last_update_submitted>
  <last_update_submitted_qc>July 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 3, 2007</last_update_posted>
  <keyword>lymphoma</keyword>
  <keyword>follicular</keyword>
  <keyword>B-cell</keyword>
  <keyword>rituximab</keyword>
  <keyword>interferon</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

